Dosage and indication “creep” with the new biologics to treat inflammatory diseases have payers enforcing strict utilization policies. Physicians counter that payers can’t dictate treatment. With even more biologics on the horizon, and drug spend spiralling upward, both sides need to seek a middle ground. The question is how?
Read more at: http://www.nxtbook.com/nxtbooks/medimedia/bh_2010summer/index.php?startid=12#/16
